Qiagen NV (QGEN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $10.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
Qiagen NV (QGEN) Stock Forecast
Analysts expect Qiagen NV (QGEN) to earn $2.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.14B. Of 12 analysts, 1 rates the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $2.66.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.83, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 8% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 8.3% |
| Buy | 0 | 0.0% |
| Hold | 11 | 91.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 6.8% and revenue estimates rise 4.7%.
- Fiscal year ending Dec 31, 2026
- $2.49
- EPS consensus, revenue $2.14B
- Fiscal year ending Dec 31, 2027
- $2.66
- EPS consensus, revenue $2.24B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.49 | $2.43 to $3.01 | 12 | $2.14B | $2.12B to $2.15B | 14 |
| Dec 31, 2027 | $2.66 | $2.57 to $3.23 | 13 | $2.24B | $2.21B to $2.28B | 15 |
Quarterly Estimates
The EPS consensus falls from $0.67 for the quarter ending Dec 31, 2026 to $0.56 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.67 | $0.63 to $0.70 | 11 | $584.80M | $557.19M to $613.20M | 11 |
| Mar 31, 2027 | $0.56 | $0.54 to $0.58 | 6 | $511.64M | $505.31M to $520.00M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.5% from $2.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.49 | $2.44 | $2.43 | $2.43 | $2.43 | +2.3% |
| Fiscal year ending Dec 31, 2027 | $2.66 | $2.61 | $2.61 | $2.61 | $2.61 | +2.0% |
| Quarter ending Mar 31, 2027 | $0.56 | $0.56 | $0.56 | $0.56 | $0.58 | -3.6% |
Frequently Asked Questions About QGEN
What is the QGEN stock forecast?
Consensus analyst estimates put Qiagen NV's EPS at $2.49 for the fiscal year ending Dec 31, 2026, on revenue of $2.14B. The consensus rating from 12 analysts is Hold.
How do analysts rate QGEN stock?
Of 12 analysts covering Qiagen NV, 1 rates it Strong Buy, 0 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from QGEN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.49, with estimates from $2.43 to $3.01 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.66, with estimates from $2.57 to $3.23 from 13 analysts.
What revenue do analysts expect from Qiagen NV next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.14B, with estimates from $2.12B to $2.15B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.24B, with estimates from $2.21B to $2.28B.
How many analysts cover QGEN?
12 analysts rate Qiagen NV stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
QGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts